LT3749308T - Klasikine fabri liga sergančių pacientų gydymas migalastatu - Google Patents

Klasikine fabri liga sergančių pacientų gydymas migalastatu

Info

Publication number
LT3749308T
LT3749308T LTEPPCT/US2019/016853T LTUS2019016853T LT3749308T LT 3749308 T LT3749308 T LT 3749308T LT US2019016853 T LTUS2019016853 T LT US2019016853T LT 3749308 T LT3749308 T LT 3749308T
Authority
LT
Lithuania
Prior art keywords
migalastat
classical
patients
treatment
fabri
Prior art date
Application number
LTEPPCT/US2019/016853T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jay Barth
Elfrida Benjamin
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65494622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3749308(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of LT3749308T publication Critical patent/LT3749308T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2019/016853T 2018-02-06 2019-02-06 Klasikine fabri liga sergančių pacientų gydymas migalastatu LT3749308T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862626992P 2018-02-06 2018-02-06
PCT/US2019/016853 WO2019157056A1 (en) 2018-02-06 2019-02-06 Treatment of patients with classic fabry disease

Publications (1)

Publication Number Publication Date
LT3749308T true LT3749308T (lt) 2024-02-12

Family

ID=65494622

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/016853T LT3749308T (lt) 2018-02-06 2019-02-06 Klasikine fabri liga sergančių pacientų gydymas migalastatu

Country Status (20)

Country Link
US (1) US20210038579A1 (enExample)
EP (2) EP4316589A3 (enExample)
JP (2) JP2021512896A (enExample)
KR (1) KR20200128675A (enExample)
CN (1) CN112203657A (enExample)
AR (1) AR114392A1 (enExample)
AU (2) AU2019217603A1 (enExample)
DK (1) DK3749308T3 (enExample)
ES (1) ES2969263T3 (enExample)
FI (1) FI3749308T3 (enExample)
HR (1) HRP20240025T1 (enExample)
HU (1) HUE064761T2 (enExample)
LT (1) LT3749308T (enExample)
PL (1) PL3749308T3 (enExample)
PT (1) PT3749308T (enExample)
RS (1) RS65103B1 (enExample)
SI (1) SI3749308T1 (enExample)
SM (1) SMT202400027T1 (enExample)
TW (1) TWI869336B (enExample)
WO (1) WO2019157056A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
JP2024525760A (ja) * 2021-07-12 2024-07-12 アミカス セラピューティックス インコーポレイテッド 小児患者のファブリー病を治療する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX351004B (es) * 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
EP3432882B1 (en) * 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
WO2018017721A1 (en) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
EA202090242A1 (ru) * 2017-07-19 2020-05-26 Амикус Терапьютикс, Инк. Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов

Also Published As

Publication number Publication date
EP3749308A1 (en) 2020-12-16
SI3749308T1 (sl) 2024-03-29
HRP20240025T1 (hr) 2024-03-29
FI3749308T3 (fi) 2024-01-18
AU2025200074A1 (en) 2025-01-30
WO2019157056A8 (en) 2020-12-03
PT3749308T (pt) 2024-01-25
EP4316589A3 (en) 2024-04-24
KR20200128675A (ko) 2020-11-16
DK3749308T3 (da) 2024-01-22
US20210038579A1 (en) 2021-02-11
EP3749308B1 (en) 2023-10-25
TW201944998A (zh) 2019-12-01
AU2019217603A1 (en) 2020-09-24
SMT202400027T1 (it) 2024-03-13
CN112203657A (zh) 2021-01-08
CA3090499A1 (en) 2019-08-15
ES2969263T3 (es) 2024-05-17
TWI869336B (zh) 2025-01-11
PL3749308T3 (pl) 2024-03-25
EP4316589A2 (en) 2024-02-07
JP2024026080A (ja) 2024-02-28
TW202537622A (zh) 2025-10-01
RS65103B1 (sr) 2024-02-29
HUE064761T2 (hu) 2024-04-28
AR114392A1 (es) 2020-09-02
WO2019157056A1 (en) 2019-08-15
JP2021512896A (ja) 2021-05-20

Similar Documents

Publication Publication Date Title
IL281773A (en) Ophthalmic composition for treatment of dry eye disease
IL271046A (en) Compounds for treating huntington's disease
EP3442577A4 (en) TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST TRANSLATION MODIFIED ANTI-VEGF FAB
EP3645121A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
EP3515505A4 (en) AAV TREATMENT BY MORBUS ALZHEIMER
SI3773558T1 (sl) Kombinirano zdravljenje artritične bolezni
DK3749308T3 (da) Behandling af patienter med klassisk fabrys sygdom med migalastat
EP3606535A4 (en) TREATMENT OF INFLAMMATORY INTESTINAL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS
LT4176877T (lt) Pacientų, sergančių fabri liga, širdies funkcijos gerinimo ir (arba) stabilizavimo būdai
IL282827A (en) Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
EP3802557A4 (en) THERAPEUTIC TREATMENT OF MICROSATELLITE-UNSTABLE CANCER
EP3503904A4 (en) ASCAROSIDE TREATMENT OF EOSINOPHILER OESOPHAGITIS
HUE058921T2 (hu) Bisz-kolin-tetratiomolibdát wilson-betegség kezelésére
IL281022A (en) Treatment of nsclc patients refractory for anti-pd-1 antibody
DK3886858T3 (da) Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering
MA53553A (fr) Traitement post-chirurgical de la douleur
EP3735209A4 (en) TREATMENT OF THE PROGRESSION OF MYOPOIA
MA42287A (fr) Traitement de patients atteints de diabète sucré de type 2
EP3458045A4 (en) TREATMENT OF MÉNIÈRE'S DISEASE
MA41782A (fr) Traitement de patients atteints de diabète de type 2
EP3840749A4 (en) METHODS OF TREATMENT OF HEART VALVE DISEASES
IL291372A (en) Treatment of chronic granulomatous disease
EP3630185A4 (en) TREATMENT OF A NEUROINFLAMMATIONAL DISEASE
EP3752113C0 (en) SURGICAL GAUZE
IL282869A (en) Use of tivozanib to treat subjects with refractory cancer